GGrantIndex
Sort

50,496 grants matching lung cancer

Predictors of CVD among breast cancer survivors in an integrated health system

$616,377
Marilyn L Kwan · Kaiser Foundation Research Institute · R01 · FY2017 · CA

Validating and Characterizing a New Melanoma Therapeutic Target

$616,207
Sara A Courtneidge · Oregon Health & Science University · R01 · FY2019 · CA

A model for predicting response to PD-1 inhibitors in NSCLC

$616,200
Edward B Garon · University Of California Los Angeles · R01 · FY2019 · CA

Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors

$616,177
Julie A Sterling · Vanderbilt University Medical Center · R01 · FY2024 · CA

SMART Cancer Care Teams: Enhancing EHR Communication to Improve Interprofessional Teamwork

$616,123
Shin-Ping Tu · University Of California At Davis · R01 · FY2024 · CA

Expression signatures of TB-specific memory responses within the human lung

$616,090
Richard F Silver · Case Western Reserve University · R01 · FY2015 · HL

Developing purinergic receptor inverse agonists for treating triple negative breast cancer

$616,071
Jean X Jiang · University Of Texas Hlth Science Center · R01 · FY2025 · CA

Late Effects of Treatment in Wilms Tumor Survivors and Offspring

$616,064
Wendy M Leisenring · Fred Hutchinson Cancer Research Center · R01 · FY2015 · CA

High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers

$616,064
Henning Willers · Massachusetts General Hospital · U01 · FY2020 · CA

Impact of mutation burden on cancer growth and the immune landscape

$615,901
Eileen White · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA

Diversity of the Tumor Microenvironment in Cancer Progression and Metastasis

$615,883
Christina S Leslie · Sloan-Kettering Inst Can Research · U54 · FY2014 · CA

Design and characterization of bacterial population dynamics in solid tumor models

$615,868
Jeff M Hasty · University Of California, San Diego · R01 · FY2024 · EB

A Randomized Trial of Incentives for Research Participation

$615,864
Scott D Halpern · University Of Pennsylvania · R01 · FY2017 · CA

Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay

$615,852
Yun Wu · State University Of New York At Buffalo · R01 · FY2024 · CA

IL-2 Family Cytokines and their Receptors--Biology of the IL-7/TSLP Systems

$615,820
Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL

Smoking cessation in lung cancer screening: integrated digital/clinical approach

$615,792
J Taylor Hays · Mayo Clinic Rochester · R01 · FY2016 · CA

Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response

$615,683
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2018 · CA

Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response

$615,683
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2021 · CA

Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response

$615,683
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2020 · CA

Evaluating Cigarette Relighting Behavior: Prevalence, Correlates, Toxicant Exposure, and Implications for Cessation

$615,659
Michael B. Steinberg · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA

Adversarially Based Virtual CT Workflow for Evaluation of AI in Medical Imaging

$615,638
Ge Wang · Rensselaer Polytechnic Institute · R01 · FY2023 · EB

Determinants of acquired resistance in small cell lung cancer

$615,628
Charles M Rudin · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

Validation and extension of an existing risk model for lung cancer

$615,470
Randa A El-Zein · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA

Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapy

$615,450
Vinod P Balachandran · Sloan-Kettering Inst Can Research · U01 · FY2020 · CA

Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC

$615,425
John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2017 · CA